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Abstract
’One Health’ proposes the unification of medical and veterinary sciences with the establishment of collaborative
ventures in clinical care, surveillance and control of cross-species disease, education, and research into disease
pathogenesis, diagnosis, therapy and vaccination. The concept encompasses the human population, domestic
animals and wildlife, and the impact that environmental changes (’environmental health’) such as global warming
will have on these populations. Visceral leishmaniasis is a perfect example of a small companion animal disease for
which prevention and control might abolish or decrease the suffering of canine and human patients, and which
aligns well with the One Health approach. In this review we discuss how surveillance for leishmaniases is
undertaken globally through the control of anthroponootic visceral leishmaniasis (AVL) and zoonotic visceral
leishmaniasis (ZVL). The ZVL epidemic has been managed to date by the culling of infected dogs, treatment of
human cases and control of the sandfly vector by insecticidal treatment of human homes and the canine reservoir.
Recently, preventive vaccination of dogs in Brazil has led to reduction in the incidence of the canine and human
disease. Vaccination permits greater dog owner compliance with control measures than a culling programme.
Another advance in disease control in Africa is provided by a surveillance programme that combines remote
satellite sensing, ecological modelling, vector surveillance and geo-spatial mapping of the distribution of vectors
and of the animal-to-animal or animal-to-human pathogen transmission. This coordinated programme generates
advisory notices and alerts on emerging infectious disease outbreaks that may impede or avoid the spreading of
visceral leishmaniasis to new areas of the planet as a consequence of global warming.
Review
What is visceral leishmaniasis?
Visceral leishmaniasis (VL) is a chronic and frequently
lethal disease caused by protozoan parasites of the
L. donovani complex, order Kinetoplastida. The aetiologi-
cal agents are: L. donovani in India and Central Africa and
L. infantum in the Americas, the Middle East, Central
Asia, China and the Mediterranean. The human disease is
lethal if not treated early after the onset of clinicopatholo-
gical abnormalities that include: malaise, anaemia,
cachexia, hypergammaglobulinaemia, hepato-splenome-
galy and progressive suppression of the cellular immune
response. L. donovani complex species are intracellular
parasites of macrophages of lymphoid organs such as
the spleen, lymph nodes, bone marrow and liver. Their
biological cycle alternates between the amastigote form in
the vertebrate host and the promastigote form in the gut
of the sandfly vector. More than 90% of human cases of
VL occur in India, Sudan, Bangladesh and Brazil. Each
year 500,000 new human cases of VL are reported [1].
Several species of vertebrate mammals may be infected
naturally with Leishmania. Canids are the main reservoirs
for the viscerotropic species in the Mediterranean, Asia,
North Africa and South America. Considering the pre-
sence or absence of animal reservoirs for Leishmania, two
basic types of epidemiological cycles are noted: zoonotic
(ZVL) or anthroponotic (AVL) [reviewed in [2]].
AVL in India and Central Africa is caused by L. dono-
vani and involves a severe parasitism of the blood and
skin and an anthropophilic vector, making man the reser-
voir of the disease. In contrast, ZVL with dogs as reservoir
hosts is usually associated with L. infantum and is found
in the Americas, the Middle East, Central Asia, China and
the Mediterranean. ZVL is considered a canid zoonosis in
which sandflies become infected mostly by feeding on the
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skin of canids and humans are the final host of the para-
sites. Blood-parasitism in people with ZVL was at first
considered not to occur [3] but has been shown recently
[4,5]. Skin parasitism has also been found in human
patients with severe patent infection, indicating they might
also act as a competent reservoir for the parasite and be
involved in the transmission cycle [6].
Visceral leishmaniasis and the One Health paradigm
‘One Health’ is a concept that is firmly rooted in the his-
tory of medicine and healthcare, but that has been redis-
covered over the past decade to now become a global
focus in biological science [7]. One Health proposes taking
a holistic view of the previously distinct disciplines of
human medicine, veterinary medicine, environmental
science and wildlife conservation. One Health recognizes
the intrinsic links between these areas of scientific endea-
vour and the impact that changes in one might have upon
the others. A major focus of One Health endeavours has
been in the area of infectious disease. It is recognized, for
example, that environmental changes (e.g. global warming,
deforestation and associated urbanization) and the effects
of such changes on wildlife species (e.g. survival, geogra-
phical range) may lead to the emergence of novel infec-
tious agents or alternative means of vector transmission of
such agents. As domestic animal and human populations
move closer to traditional wildlife habitats, the risk of
cross-species transfer of novel infectious agents increases.
It is widely recognized that the majority of emerging
human infections will derive from wild or domestic animal
sources [8]. In order to identify, characterize and under-
take surveillance for emerging infections, and to develop
integrated strategies for the control and prevention of the
associated diseases, a One Health approach becomes
imperative. In such situations, it is essential that interdisci-
plinary teams of medical, veterinary and environmental
scientists work together to address the problems. The One
Health concept has now been widely endorsed by key
organizations such as the World Health Organization
(WHO), the World Organization for Animal Health
(OIE), the Food and Agriculture Organization (FAO) and
the US Centers for Disease Control and Prevention
(CDC). One Health is promoted through the activities of
the US One Health Commission, the US One Health
Initiative and the One Health Committee of the World
Small Animal Veterinary Association (WSAVA) [9]. The
first international One Health Conference was held
recently in Melbourne, Australia and provided a global
focus for this cross-disciplinary endeavour.
ZVL is a disease that epitomizes perfectly the need
for a One Health approach and we hope that this will
become clear in the discussion that follows. This is a dis-
ease of major human and veterinary medical significance
that involves a complex interplay between a protozoal
pathogen, arthropod vectors, environmental influence
on vector distribution, a small companion animal (dog)
reservoir of infection and susceptible human populations.
The effective control of ZVL will essentially involve inter-
disciplinary teams of microbiologists, parasitologists, ento-
mologists, ecologists, epidemiologists, immunologists,
veterinarians, public health officers and human physicians.
More importantly, the One Health approach fits perfectly
the requirements for surveillance and control of this infec-
tion. The present review examines the current state-of-
the-art in surveillance, control and prevention of VL, but
also highlights the deficiencies in these areas that might be
addressed through application of One Health principles.
How surveillance for leishmaniasis is done globally
through the control of the anthroponootic human
disease (AVL)
Geographically, VL occurs in 88 countries around the
world, of which 60 per cent of disease foci are in well-
defined areas of Bangladesh, India and Nepal. In AVL,
untreated patients are the sole sources of infection for the
vector [10]. These foci of AVL are the origin of the most
severe and deadly epidemics. In the 1960s, during the
malaria eradication programme and due to the adoption
of intensive vector control measures AVL was almost
eliminated in this region, illustrating the vulnerability of
the transmission cycle. The control/elimination strategy
for AVL is based on aggressive identification of cases,
effective management and vector control measures for
reduction of, not only morbidity and mortality, but also
disease transmission. The use of simple, reliable and inex-
pensive tests for field-level serological diagnosis, new
orally-administered drugs and long-lasting insecticide-
impregnated bed nets is expected to substantially decrease
the number of cases, reduce transmission and prevent epi-
demics. In 1991-1992, an enhanced effort by the Govern-
ment of India combining widespread availability and easy
accessibility of drugs (antimonials), and spraying of houses
with DDT, led to a 67.7 percent reduction in morbidity
and 73.3 percent reduction in mortality by 1995 [10].
Recently, the governments of India, Bangladesh and
Nepal launched an AVL elimination initiative, aiming to
reduce the annual incidence to less than 1/10,000 popu-
lation by 2015 [10]. Bihar, being the second largest
populated State in India, has reported as many as
200,000 deaths from AVL since 1977. The burden of
disease in India was estimated as 15 and 11 thousand
new cases per year in 2001 and 2002, respectively.
Approximately 1850 cases occur in Nepal annually and
30,000 in Bangladesh [10]. The difficulty of controlling
AVL in the past in this region was attributed to a com-
bination of factors including: lack of political will, non-
availability of reliable diagnostic tests and unresponsive-
ness to antimonials, as well as inadequate vector control.
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The second-line drug amphotericin B is prohibitively
costly and requires intravenous administration and hos-
pitalization. In patients recovered from AVL, post-infec-
tion dermal leishmaniasis is recognized and these
individuals may act as a potential reservoir of infection.
The proposed control strategy exploits recent technolo-
gical developments in diagnosis, drug development and
vector control. The transmission pattern in this region
involves P. argentipes as the sandfly vector [10].
Africa is also one of the main areas of AVL and has
lately experienced the benefit of very modern methods of
disease surveillance. The Armed Forces Health Surveil-
lance Center, Division of Global Emerging Infections
Surveillance and Response System Operations, USA
(AFHSC-GEIS) [11] initiated a coordinated, multidisciplin-
ary programme to link datasets into a predictive surveil-
lance programme that generates advisory notices and
alerts on emerging infectious disease outbreaks. The activ-
ities of this group combine: (1) satellite remote sensing
and ecological niche modelling for ecological and climatic
events that influence the potential for disease outbreaks;
(2) arthropod-vector surveillance and geo-spatial mapping
for characterizing vector presence, abundance and disease
transmission capability; and (3) animal-host surveillance
for detecting vector and pathogen exposure events and
animal-to-animal or animal-to-human pathogen transmis-
sion [11]. This model has successfully predicted outbreaks
of Rift Valley fever. The WHO and FAO are currently
using the programme’s Rift Valley fever advisory notices
and alerts to prepare for and mitigate the impact of out-
breaks of Rift Valley fever in Africa [11]. The National
Aeronautics and Space Administration (NASA) Goddard
Space Flight Center monitors global-scale indicators of cli-
mate variability and generates data on land surface tem-
perature, normalized difference vegetation index, sea
surface temperature and rainfall that signal the persistence
of an eco-climatic trend with known associations to dis-
ease outbreaks. A risk assessment is performed on the
basis of these data. While the programme’s vector surveil-
lance activities are centred historically on mosquitoes (Rift
Valley fever and Malaria), in 2009 they expanded to
include the sandfly vectors of leishmaniasis [11]. Large-
scale surveillance of over 200 sites in Kenya captured
3,500 sandflies that were tested for Leishmania spp. infec-
tion using polymerase chain reaction (PCR) techniques.
This traditional surveillance work forms the basis for
future predictive surveillance for leishmaniasis in that
country and potentially elsewhere in sub-Saharan Africa
[11]. To date, there have been two major findings with epi-
demiological and predictive surveillance implications in
Kenya. Firstly, Leishmania major-infected sandflies were
detected in two regions not previously known for Leish-
mania transmission: Isiolo and Lamu. Secondly, Phleboto-
mus orientalis, a known vector of VL in Sudan, but rare in
Kenya, was detected in large numbers in Isiolo and in
Garissa [11]. Furthermore, reports from the northeast of
Kenya on possible cases of AVL among refugees from
Ethiopia and Somalia started to occur after the 1997,
2000-2001 and 2006-2007 El Niño rainfalls and possibly
historically since the 1930s [11]. If a temporal relationship
exists between El Niño events, sandfly activity and out-
breaks of leishmaniasis this finding will provide a solid
foundation for expanding predictive surveillance capability
in Kenya beyond the Rift Valley fever project [11].
Zoonotic visceral leishmaniasis (ZVL)
ZVL is one of the most important emerging diseases [12]
that is caused by Leishmania infantum and transmitted
by phlebotomine sand flies from a canine reservoir [6].
American and European ZVL affects mainly children and
young adults [reviewed in [2]]. In Europe the majority of
cases occur in adult patients with HIV infection or symp-
tomatic acquired immunodeficiency syndrome (AIDS)
[13] or in organ transplant recipients with immunosup-
pression [14] and in children [15].
Epidemiological studies of ZVL indicate that there
appears to be an increased prevalence of L. infantum
infection with increasing age of dogs [16-19], although
this was not the case in a study of 33,937 dogs in Brazil
[20]. No specific canine gender predisposition has been
described for ZVL in several endemic countries
[16,19,21,22]; however, in France a greater prevalence of
ZVL was found in male dogs [17] and in an endemic area
of Brazil high rates of seropositivity were found among
male animals [23].
The German shepherd dog [18,21] together with the
boxer [18] and doberman [19,21] appear to be dog breeds
predisposed to infection in France, Portugal and Greece.
In contrast, in Greece dogs of the collie breed are infected
rarely [19] and there is a well-known resistance in Ibizian
hounds in Spain [24]. In Brazil however, the most affected
breeds are the long-coated cocker spaniel (26.9%) and the
short-coated boxer (24.6%) [20], while in Italy no breed-
related predisposition is reported [16]. A role of dog
genetics in resistance or susceptibility to disease following
infection appears likely. Candidate genes such as Slc11a1
(solute carrier family 11 member a1) [25] and the poly-
morphic genes of the major histocompatibility complex
(MHC) [26] have been analyzed in relation to susceptibil-
ity to ZVL. Slc11a1, formerly known as Nramp1/Ity/Lsh/
Bcg, is a proton/divalent cation antiporter that regulates
susceptibility to infectious and autoimmune disease [27].
It was originally described in mice for its roles in regulat-
ing resistance and susceptibility to Salmonella, Leishmania
and Mycobacterium. Functional studies with murine
Slc11a1 implicate its involvement in macrophage function,
including up-regulation of chemokines and cytokine
genes, such as those encoding tumour necrosis factor
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(TNF)-a and interleukin (IL)-1b, and induction of nitric
oxide synthase (iNOS) [reviewed in [28]]. Explaining the
previous results of higher prevalence of infection in boxers
[18,20] Sanchez Robert et al. [28] reported that the most
frequent haplotypes of SLc11a1 included TAG-8-141,
which was present in all breeds, in both case and control
animals; and TAG-9-145, which was overrepresented in
the control population and found mostly in boxer dogs.
Within the boxer breed, 81% of healthy dogs were homo-
zygous for TAG-9-145, whereas TAG-8-141 was signifi-
cantly associated with case boxers. The TAG-8-141
genotype determined higher prevalence of the illness in
the boxer breed, disclosing the importance of breed
genetic background in susceptibility to ZVL [28]. A major
study of the genetic basis for susceptibility to canine leish-
maniasis, applying the technique of the genome-wide asso-
ciation study (GWAS), is nearing completion as part of the
European Union-funded LUPA project [29].
Recently ZVL has become an emerging problem in some
dog breeds in the USA and Canada [30,31], with an annual
quantitative PCR prevalence of greater than 20% within an
at-risk Foxhound population [25]. Although classically,
Leishmania is transmitted by infected sandflies, and phle-
botomine sandflies are known to exist in the USA, means
of ongoing L. infantum transmission in North American
dogs is currently unknown. Although the vertical (trans-
placental or transmammary) routes of transmission were
not considered possible [32], several reports have indicated
that endemic ZVL may be transmitted vertically [30,33].
Boggiato et al. [30] described disseminated L. infantum
parasites as identified by PCR in 8-day-old pups born to a
naturally-infected, seropositive American dog with no
travel history. This was the first report of vertical transmis-
sion of L. infantum in naturally-infected dogs in North
America. In Brazil, Andrade et al. [32] reported a kennel
study with experimental infection where vertical trans-
mission did not occur and conversely, da Silva et al. [33]
reported the first case of vertical transmission of L. infan-
tum, confirmed by PCR and immunohistochemistry tech-
niques in two stillborn pups from a bitch naturally
infected with L. infantum. L. infantum has also been trans-
mitted between dogs venereally [34] and by blood transfu-
sion [35].
Canine cases of leishmaniasis have also been reported
in traditionally non-endemic northern European coun-
tries (e.g. The Netherlands and the United Kingdom)
[36-40], where traditional sandfly vectors are thought
not to exist. The large-scale movement of pet dogs
under the European Pet Passport scheme, coupled with
predictions on climate change in northern European
countries, has led to concerns that canine leishmaniasis
may become an established infection in these areas in
the future [36,37].
Impact of control of the canine reservoir on the incidence
of human and canine disease
ZVL is endemic in the Mediterranean basin, Middle East
and South America, and the prevalence of Leishmania
infection can reach 67% in these areas [28]. Moreover,
leishmaniasis is emerging within non-endemic areas
mostly because of transportation of dogs from endemic
areas and climatic changes with the expansion of the geo-
graphical range of the sandfly vector. Hence ZVL has
been reported in many countries in Europe including the
United Kingdom [41] and in North America particularly
in English and American foxhounds and hunting dogs
[31,42,43]. Cases of human ZVL have also been reported
from Honduras, Venezuela, Paraguay and Argentina.
Sporadic and/or imported human or canine cases have
been described in Chile, Ecuador, Bolivia, Mexico, Costa
Rica and French Guyana [44]. A geographically-refer-
enced database providing links to published literature
about the spatial distribution of VL was recently pub-
lished by the WHO [45]
For the control of leishmaniasis the WHO recom-
mends: (1) the treatment of human patients, (2) the cul-
ling of seropositive infected dogs and (3) the insecticidal
treatment of human homes [2,12]. The epidemiological
control of ZVL is performed with different tools in differ-
ent countries. In the Americas, control of ZVL has pro-
ven to be particularly challenging.
Early diagnosis and treatment is essential for the
human patient, but this has limited impact on transmis-
sion if the dog reservoir or insect vectors are not tackled
[2,44,46]. Since dogs are the main reservoirs of the infec-
tion, a decreased incidence of ZVL in both dogs and chil-
dren is found following serological screening and culling
of seropositive dogs [2,47-50]. It was suggested that the
incidence of human cases could be even lower if such
campaigns used canine diagnostic tests with enhanced
sensitivity and if there was no delay between diagnosis
and culling [2,48-51]. However, as reported by Romero &
Boelaert [44] and by Quinnell and Courtenay [40], the
dog culling control strategy is increasingly debated. The
incidence of human ZVL has remained high in Brazil
despite intensive application of this strategy in recent
years. Romero & Boelaert [44] also state that the elimina-
tion of ZVL in the Americas does not seem a realistic
goal given the lack of political commitment, gaps in
scientific knowledge, and the weakness of case manage-
ment and surveillance systems [44]. Mathematical model-
ing suggests also that vector control and vaccination of
dogs would be more efficacious than dog culling [46].
Initially, several studies correlated the practice of culling
to the decrease in human and/or canine incidence of ZVL
[47,49,51-54]. Magalhães et al. [49] defended the systema-
tic use of dog culling, insecticide spraying and human
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treatment for eradication of the disease. Jerónimo et al.
[50] reported a concomitant decrease in human pediatric
cases of ZVL and of infected dogs. Braga et al. [51]
reported that reduction of canine seroprevalence was
higher when an enzyme-linked immunosorbent assay
(ELISA) was used for testing and the removal of seroposi-
tive dogs was conducted more rapidly. Using an ELISA
and removal of seropositive dogs, Ashford et al. [47]
observed a significant decrease in canine seroprevalence
and human incidence of disease. De Oliveira et al., [53]
showed that the percentage of buildings visited during the
survey, the insecticidal spraying of these buildings, and the
number of annual canine serological surveys were the
most effective variables in reduction of the number of
human cases. Costa et al., [54] described that in compari-
son to areas receiving only household insecticide spraying,
culling dogs decreased the incidence of infection by 80%
[54]. However, the mathematical model described by Dye
[46] condemned the epidemiological ZVL control cam-
paign, considering it non-efficient and indeed, at low rates
of canine seropositivity, no impact on the human inci-
dence of the disease was observed [48]. The control cam-
paign uses for the indirect immunofluorescence test (IFT),
blood eluates which are saline eluates of canine blood
samples collected by the survey on Whatman filter paper.
However, with higher rates of canine seropositivity, corre-
sponding to IFT or ELISA results with dog sera, the num-
ber of infectious dogs declined interrupting the
transmission and the spread of epidemics [48]. Experimen-
tal results using sera instead of blood eluates lead to a 57%
decrease in canine and 87.5% decrease in human cases
[48]. Furthermore, Nunes et al. [55] described a decrease
in the incidence of human ZVL that was correlated statis-
tically to the euthanasia of dogs [55]. The effect of the
insecticidal treatment of dogs was also considered impor-
tant. A decrease in the prevalence of canine ZVL was
observed after 65% permethrin spot-on treatment of dogs
[56] and a significant reduction of anti-Leishmania anti-
body titres in dogs was observed in dogs using insecticide-
impregnated collars [57].
On the other hand, several other experimental investiga-
tions did not support a correlation between dog culling
and the reduction of human or canine incidence of ZVL
[44,52,58-60]. The experiment of Dietze et al. [58] con-
cluded that the elimination of seropositive dogs did not
modify the incidence of human seroconversion or human
disease, suggesting the possible involvement of other
reservoirs of infection [58]. Moreira et al. [59] did not
achieve a significant change in the incidence of canine
infection despite the use of a more sensitive ELISA on
serum samples; a reduced interval from serodiagnosis to
removal of dogs and a higher proportion of screened dog
population. The immigration of infected dogs into the
study area was considered an important factor [52,59]. De
Souza et al. [60] not find statistically significant differences
on human infant seropositivy between an untreated area,
an area subjected to insecticide spraying and an area sub-
jected to the combination of insecticidal spraying and
elimination of seropositive dogs [60].
Despite the fact that dogs are considered to be the main
reservoir for L. infantum, the vector Lutzomyia longipalpis
is opportunistic and can feed on blood from humans [6],
opossums and oxen [61] making these animals also poten-
tial reservoirs. Indeed, the ability to transmit infection has
been confirmed in humans, in the crab-eating fox Cerdo-
cyon thous, in oppossums of Didelphis spp., in the black
rat Rattus rattus and in the domestic cat Felis catus how-
ever, no xenodiagnosis results confirm their relevance as
primary or secondary reservoirs [reviewed in [40]].
In a very detailed review of the control of ZVL, Quinnell
and Courtenay [40] reported that despite the large invest-
ment in dog culling, very few randomized, controlled stu-
dies assessing its efficacy have been performed and that
these intervention trials did not reduce transmission to
zero [40]. Most of these studies were undertaken in Brazil.
The overall proportion of infectious dogs was however
considered to be higher in Europe than in South America,
reflecting a higher proportion of infected sandflies in
Europe and therefore suggesting a greater susceptibility of
P. perniciosus than of L. longipalpis [40]. Furthermore, an
alternative means of transmission is suggested to occur in
Cyprus where ZVL was nearly eradicated by dog and
vector destruction in 1996 and where a nine-fold increase
in canine seroprevalence was observed 10 years later, with
human cases mainly caused by L. donovani and not by
L. infantum. This finding indicated that there were two
transmission cycles running in parallel on the island: in
dogs with L. infantum infection and in humans with
L. donovani infection [62].
An extreme example of the efficacy of dog culling is the
case of China that had approximately 530,000 human
cases of ZVL in 1951, but only 48 cases registered in 1979
after a nationwide campaign that involved mass treatment
of patients, elimination and prohibition of reservoir dogs
and widespread spraying of insecticides [63,64]. However,
since the campaign was not systematically sustained, in
2008 a new outbreak of ZVL in children of Jiashi county
was reported and investigated [63]. These campaigns are
very expensive and laborious and their efficiency and feasi-
bility are frequently reviewed and, for humane reasons
lack compliance of the dog owners [12].
How global surveillance for leishmanioses is linked to the
control of the dog disease (ZVL)
In America and Europe ZVL is a canine-human zoonosis
transmitted via an arthropod vector. Surveillance and con-
trol of the disease in the canine population should there-
fore then be a powerful tool for reduction of availability of
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parasites to sandflies and for the subsequent reduction in
incidence of the human disease. At present, the removal of
infected dogs is undertaken systematically only in Brazil
[2,44] and may eventually extend to other South American
countries [44]. In China dog removal is now performed
only after outbreaks of ZVL in defined epidemic regions
[63]. On the other hand, limited studies have been per-
formed in the Mediterranean basin to evaluate the
decrease of canine and human infection with different
control methods or with treatment. Treatment of indivi-
dual pet dogs is intensively practiced in Europe [65] and
reduces clinical disease, parasite load and infectivity to
sandflies [65,66]; however, treatment does not prevent
relapse of disease [67]. It is likely that a combination of
control methods will be required for eradication of the dis-
ease in the Mediterranean.
In Brazil, the methodology for epidemiological surveil-
lance of ZVL is based on the classification of geographi-
cal areas with or without transmission of the disease [68].
The most recent approach of this program includes iden-
tification of “silent” regions where occurrence of human
or canine cases of ZVL has never been reported and con-
sequently no control measures have ever been applied
[68]. There are also other areas under investigation that
are considered potentially susceptible to ZVL. These
include: (1) vulnerable areas with no autochthonous
cases of human or canine ZVL, but that are contiguous
to or located in the same road axis as municipalities with
ZVL or that have a high migratory flux; (2) non-vulner-
able areas, which lack the former conditions; (3) receptive
areas that after entomological surveillance showed the
presence of the specific insect vectors L. longipalpis or
L. cruzi and (4) non-receptive areas which lack these
insect vectors [68]. In areas with active transmission of
ZVL, the average number of human cases over the past 5
years is used as a monitoring indicator [68]. A stratifica-
tion was performed into five categories: (1) areas with the
first registered autochthonous human case; (2) areas of
sporadic disease (> 0.1 and < 2.4 human cases), (3) areas
of moderate disease (≥ 2.4 and < 4.4 human cases), (4)
areas of intense transmission of disease (≥ 4.4 human
cases) and (5) outbreak areas, which are municipalities
showing a number of cases greater than expected. This
stratification is revised annually based on the average
incidence over the last 5 years [68].
It is noteworthy that in Brazil, until 1993 95.4% of ZVL
cases were restricted to the north and north east of the
country, while in 2003, these areas had only 78.1% of the
cases and there was an increase to 21.8% of ZVL cases in
the south east and central west region of the country
[68]. This expansion was a consequence of the construc-
tion of a major road that crosses the country and that
allowed the migration of people with their infected dogs
to new areas with the appropriate sandfly vector. Canine
epidemics always precede human epidemics [69] and this
is what occurs currently in the Brazilian states of Matto
Grosso do Sul, São Paulo and Minas Gerais (south east
and central west of Brazil) [68].
One of the preventive actions of the control campaign
in Brazil is the monitoring of the sandfly vector in
human residences and peri-domestic areas in order to
evaluate the seasonal distribution of L. longipalpis and/or
L. cruzi, so as to define the highest transmission periods
and to inform prevention by chemical control of the vec-
tor. This control is achieved by spraying with pyrethroids
(e.g. deltamethrin, lambdacyalothrin, alfacypermethrin,
cypermethrin, cyphluthrin and betacyphluthrin) [70].
The use of deltamethrin-impregnated collars in dogs and
of nets (with or without insecticides) in human homes
and dog kennels is recommended, but these are not used
as official tools.
A second preventive tool for ZVL in Brazil is control of
the canine reservoir by removal and humane destruction
of the Leishmania-seropositive and/or infected dogs and
elimination of their carcasses [70]. To verify the presence
of the canine disease a serological survey is performed. If
the result is negative the areas are monitored by biannual
serosurveys. If, on the other hand, the canine disease is
present, the parasite is identified by a reference labora-
tory. In this case, the seropositive dogs are humanely
destroyed and preventive actions are started by Public
Health officers. If the case is autochthonous, the active
search for and humane destruction of seropositive or
parasite-positive dogs is performed; education of dogs
owners is promoted and a serosurvey is performed in
areas where the prevalence of seropositivity in the canine
population is above 2% [70].
Finally, any human cases are diagnosed and treated as
swiftly as possible. The identification of human cases by
passive reporting or by active investigation is of para-
mount importance in areas of higher risk or where access
of the population to treatment is problematic [70].
The low acceptance of culling of companion animals by
their owners, the ethical dilemmas of veterinarians and
humane reasons demand the development of alternative
preventive tools. Mathematical modelling suggests that
vector control and vaccination of dogs would be more
efficacious than dog culling [46]. Limited data are avail-
able to judge whether treatment of individual dogs is an
effective strategy for controlling infection.
Many Leishmania antigens have been identified as
potential vaccine candidates [reviewed in [71]], but very
few have been tested in field assays. First generation Leish-
mania vaccines using BCG [72] or muramyldipeptide [73]
adjuvants failed to prevent ZVL in Brazil and France,
respectively; while the use of alum-adjuvanted BCG
resulted in a vaccine efficacy of 69.3% against the canine
disease in Iran [74]. The vaccine efficacy of a double
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blind-control trial in the field is the result of the calcula-
tion of the incidence of disease in vaccinated subjects-the
incidence of disease in controls/the incidence of disease in
controls × 100. A second generation vaccine composed of
L. infantum antigen in combination with muramyldipep-
tide (LiESAp) had a vaccine efficacy of 92% as determined
by the use of sensitive molecular diagnostic methods in an
endemic area where no deaths or severe cases of ZVL
occurred, indicating a low infective pressure [75]. There is
only a single report of the impact of the use of a Leishma-
nia vaccine on the incidence of human and canine ZVL
[76]. Leishmune®, the first prophylactic vaccine licensed
against canine visceral leishmaniasis (CVL), has been used
in Brazil since 2004. The possible additive effect of Leish-
mune® vaccination over dog culling, on the decrease of
the incidence of canine and human ZVL was studied in
two Brazilian endemic areas, from 2004 to 2006 [76]. In
Araçatuba a decline in the incidence of ZVL in dogs of
25% was seen with a 61% decline in human cases (36 to 14
cases), indicating the additive effect of Leishmune® vacci-
nation on regular dog culling. In Belo Horizonte, where
8.1% (12,113/149,470) of the dogs were vaccinated up to
2006, the districts that had had greater vaccine coverage
(85.7% of the doses) exhibited declined or sustained levels
of canine and human cases of ZVL, while those with less
vaccine coverage (14.3% of the doses), showed rising
curves of canine and human cases of the disease. In the
districts with higher vaccination levels, human cases
declined by 36.5% falling from 2004 to 2006 outside of the
95% confidence interval (CI95%) of the less vaccinated dis-
tricts (CI95% 2.23-21.11), which showed an average
increase of 11.67%. From 1999 to 2006, the increase of
canine seroprevalence and of human cases of the disease
in all districts were significantly correlated (p = 0.001),
confirming the importance of the dog as the infectious
reservoir of the disease. The decrease in dog culling (-p =
0.007) and human incidence (-p = 0.043) were significantly
correlated with the increase in the number of vaccinated
animals, indicating the prophylactic impact of Leishmune®
vaccination on the decrease of the range of infectious dog
and human populations, and so indirectly indicating a
decrease in the number of dogs sacrificed. Dogs vaccinated
with Leishmune® did not become seroreactive in the test
used by the epidemiological control campaign [76].
A vaccine called Leish-Tec® has also been licensed in
Brazil. It is composed of the recombinant A2-antigen of
Leishmania amastigotes and is adjuvanted by saponin [77].
While protection due to the Leishmune® vaccine has been
extensively investigated in laboratory models [reviewed in
[78]], explained through an immunological approach
[79-82] and reported in: control versus trial-field assays
with cohorts including 117 [83], 85 [84], 72 [85], and 1138
dogs [86]; immunotherapy assays with 66 [87] and 24 dogs
[88]; and in 19392 vaccinated dogs in two Brazilian towns
[76], there is only one report of an experimental kennel
assay with Leish-Tec® which was tested on seven dogs
and compared with four untreated controls [77]. There is
no information about the infectivity of the strain used for
challenge in that study [77] and the lack of deaths in the
control animals suggests that the challenge was mild.
There are no reports of controlled-trial field studies with
Leish-Tec®, but despite of the lack of peer-reviewed scien-
tific publications, the vaccine was licensed in Brazil in
2008.
While in Brazil an average of 4,000 human cases of ZVL
is reported annually, in Europe, the incidence of human
ZVL is relatively lower, with a total of approximately 700
reported new cases per year for all southern European
countries [89]. An estimated 2.5 million Leishmania-
infected dogs are thought to reside in Italy, Spain, France
and Portugal as determined by published serological sur-
veys from those countries [90]. Autochthonous human
and canine ZVL have spread northward, as shown by the
recent reports of indigenous cases of VL in northern Italy
[15] northern France [91], north western Spain [92] and
southern Germany [36]. The European Centre for Disease
Control is currently assessing the magnitude and impor-
tance of vector-borne diseases in Europe, mainly due to
the predicted effects of global warming. Existing auto-
chthonous vector-borne infections such as ZVL should be
controlled. The risk of introducing ZVL into currently
non-endemic areas of the European Union (EU) and its
spread among member states was assessed for the short
(2-3 years) and long term (15-20 years) [37]. In southern
Europe the use of deltamethrin-impregnated dog collars
[93,94] is preferred by many dog owners. Alternatively,
there is substantial evidence for the efficacy of spot-on
repellents containing imidacloprid, permethrin, pyriprole,
metaflumizone or amitraz [95-97]. In the Mediterranean
region, human and canine cases of ZVL are treated with
antiparasitic drugs. In Europe, individual measures to pro-
tect dogs from sandfly bites using insecticides are com-
monly practiced, but no public health surveillance and
control interventions such as those applied in Brazil are in
place [44]. In 2011, the first European licensed canine
Leishmania vaccine is due to be released in selected coun-
tries endemic for the disease [29]. It will be interesting to
monitor the effect that this product may have on the epi-
demiology of the disease in those areas.
In Iran, ZVL is not controlled by serological testing
and culling infected dogs, but by the use of deltame-
thrin-impregnated dog collars. These measures were
reported to reduce the risk of infection in dogs by 54%
and in children by 43% [98].
Conclusions
The control of Leishmania infection in the domestic dog
population is fundamental in order to avoid the spread
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of ZVL between dogs and man. A high level of infection
in dogs, particularly in impoverished areas, is often
recorded just before the start of a human epidemic and
may be an important predictor of an impending out-
break of disease in the human population [69]. It is
clear that identification and removal of infected dogs
would reduce the prevalence of human ZVL, but recent
research demonstrates that the use of insecticides in
human residences and the use of insecticidal dog collars
and/or the use of a preventive canine vaccine could
potentially substitute for dog culling. In any case, the
surveillance and control of the disease in the domestic
dog is key to reducing the incidence of human disease.
The One Health concept is a worldwide strategy for
expanding interdisciplinary collaborations and communi-
cation in all aspects of health care for man, animals and
the environment. As monitoring of ZVL in companion
animals is extremely important for the control and preven-
tion of the human disease, ZVL is one of the best exam-
ples of a disease whose successful control and eradication
depends upon the use of a One Health strategy.
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